Ayşe GÖKYİĞİT, Seyide Rumeysa DEMİRDAMAR

Epidemiology and cost of drug treatment of cancer in Northern Cyprus

Background/aim: To determine the epidemiology, the sociodemographic features, the incidence and prevalence rate of cancer, and the cost of drug treatment in Northern Cyprus. Materials and methods: All of the oncology prescriptions, cancer pathology reports, and cancer referrals to overseas for 2011 were collected from the state hospitals, the only private university hospital that provides oncology services, and the Ministry of Health to prepare an epidemiological database. The total cost of drug treatment at the state hospitals and cost of the most frequent five cancer types were also calculated using the therapy protocols and the expense of the drugs. Results: The total incidence rate for all cancer cases in 2011 was 201 per 100,000 and the prevalence rate was 460 per 100,000. The five most common cancer types were breast (19.8%), prostate (12.6%), colorectal (9.7%), thyroid (6.4%), and lung (5.6%). The cost of drug treatment for cancer at the state hospitals comprises 25% of the total medical budget of the Directorate of Pharmaceuticals. Almost 1/3 of this amount was spent on drug treatment of breast cancer. Conclusion: Breast cancer is the most frequent and the most costly cancer type in Northern Cyprus. Of all the districts, the GüzelyurtLefke District has the highest cancer rate.

PDF

___

1. Mokarian F, Ramezani MA, Heydari K, Tabatabaeian M, Tavazohi H. Epidemiology and trend of cancer in Isfahan 2005-2010. J Res Med Sci 2011; 16: 1228-1233.
2. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a populationbased cost analysis. Lancet Oncol 2013; 14: 1165-1174.
3. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of the cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011; 103: 117-128.
4. Jönsson B, Wilking N. The burden and cost of cancer. Ann Oncol 2007; 18: iii8-iii22.
5. Boffetta P. Environment and cancer risk. Rev Prat 2013; 63: 1122-5.
6. Boffetta P, Nyberg F. Contribution of environmental factors to cancer risk. Brit Med Bull 2003; 68: 71-94.
7. KKTC Sağlık Bakanlığı, Sağlık Sorunlarının Yaygınlığı Araştırması-2010, KADEM, Ekim-Aralık, 2010.
8. Hinçal E, Taneri B, Taneri U, Djamgoz MBA. Cancer incidence in North Cyprus (1990-2004) relative to European rates. Asia Pac J Cancer Prev 2008; 9: 725-732.
9. Akun ME, Fahrioğlu-Yamacı R, Charalambus C, Lechtvich S, Djamgoz MBA. The Distribution of Carcinogenic Heavy Metals in Cyprus Soil. In: Gökçekuş H, Turker U, LaMoreaux JW, editors. Survival and Sustainability: Environmental concerns in the 21st Century. Germany: Springer; 2010. pp. 353-359.
10. Budroni M, Sechi O, Cossu A, Palmieri G, Tanda F, Foschi R, Rossi S. Estimates of cancer burden in Sardinia. Tumori 2013; 99: 408-415.
11. Keskin Ö, Aksoy S. Meslek ilişkili kanserler. Hacet Tıp Derg 2011; 42: 173-179 (article in Turkish with an English abstract).
12. Yao R, Chiu CG, Strugnell SS, Gill S, Wiseman SM. Gender differences in thyroid cancer. Expert Rev Endocrinol Metab 2011; 6: 215-243.
13. Wook JC, Jeongseon K. Dietary factors and the risk of thyroid cancer: a review. Clin Nutr Res 2014; 3: 75-88.
14. Lukas J, Drabek J, Lukas D, Dusek L, Gatek J. The epidemiology of thyroid cancer in the Czech Republic in comparison with other countries. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013; 157: 266-275.
15. Roehrborn CG, Black LK. The economic burden of prostate cancer. Brit J Urol Int 2011; 108: 806-813.
16. Warren JL, Yabroff KR, Meekings A, Topor M, Lamont EB, Brown ML. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 2008; 100: 888-897.
17. Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the US: estimates, projections, and future research. Cancer Epidem Biomar 2011; 20: 2006-2014.